Sesen Bio Investor Relations Material
Latest events
Investor Update
Sesen Bio
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Sesen Bio Inc
Access all reports
Sesen Bio is developing fusion protein therapeutics for the treatment of patients with cancer based on a proprietary platform technology. This technology utilizes proprietary ligand design, a data-driven computational approach to molecular modeling, and molecular engineering to develop a library of novel fusion protein therapeutics. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
SESN
Country
🇺🇸 United States